# CVRx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cvrx

- Industry: Medical Devices & Equipment
- Headquarters: Minneapolis, US
- Website: www.cvrx.com
- Total disclosed funding: $252M
- Latest round: Series G (Jul 1, 2020)
- Investors on record: 19

## About

Based in Minnesota, US, CVRx, Inc. was founded in 2001. The company is a private medical device company that is treating chronic heart failure ("HF") and resistant hypertension in individuals. The company has a total of 9 funding rounds as of July 2020. In April 2021, the company filed on NASDAQ to become a public company.

The company's technology Barostim neo™ is designed to treat high blood pressure and heart failure by triggering the body's own natural blood flow control mechanism, allowing patients to begin therapy sooner and increasing the probability of a good outcome.

The company plans to be listed on the Nasdaq under the symbol CVRX.

## Funding rounds

- Series G, Jul 1, 2020, $50M — New Enterprise Associates, Gilde Healthcare, Hatteras Venture Partners, Johnson & Johnson Innovation, Action Potential Venture Capital, Treo Ventures, Vensana Capital, Venrock Healthcare Capital Partners
- Series G, May 31, 2018, $11M — New Enterprise Associates, Johnson & Johnson Innovation, Ysios Capital Partners, Windham Venture Partners, Action Potential Venture Capital, Glide Healthcare
- Series F, Oct 30, 2013, $12M — Ysios Capital Partners, DaVita Inc.
- Series E, Jul 29, 2008, $84M — Frazier Healthcare Partners, InterWest Partners, New Enterprise Associates, SightLine Partners, Johnson & Johnson Innovation, TWP Private Wealth Management, Sterling Capital Funds
- Series D, May 11, 2007, $65M — Frazier Healthcare Partners, InterWest Partners, New Enterprise Associates, ABS Ventures, SightLine Partners, Johnson & Johnson Innovation, TWP Private Wealth Management
- Series C, May 5, 2006, $30M — Frazier Healthcare Partners, InterWest Partners, New Enterprise Associates, ABS Ventures, SightLine Partners, Kearny Venture Partners

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series C, Series D, Series E
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series C, Series D, Series E
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series C, Series D, Series E, Series G
- ABS Ventures (https://capitalatlas.ai/funds/abs-ventures) — Series C, Series D
- SightLine Partners — Series C, Series D, Series E
- Kearny Venture Partners (https://capitalatlas.ai/funds/kearny-venture-partners) — Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series D, Series E, Series G
- TWP Private Wealth Management (https://capitalatlas.ai/funds/twp-private-wealth-management) — Series D, Series E
- Sterling Capital Funds — Series E
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series F, Series G
- DaVita Inc. — Series F
- Windham Venture Partners (https://capitalatlas.ai/funds/windham-venture-partners) — Series G
- Action Potential Venture Capital (https://capitalatlas.ai/funds/action-potential-venture-capital) — Series G
- Glide Healthcare — Series G
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series G
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series G
- Treo Ventures (https://capitalatlas.ai/funds/treo-ventures) — Series G
- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series G
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series G